Variation in cisplatinum sensitivity is not associated with Fanconi Anemia/BRCA pathway inactivation in head and neck squamous cell carcinoma cell lines

Cancer Letters

Volumn 245, Issue 1-2, 2007, Pages 75-80

  Snyder, Eric R ^a,b   Ricker, Justin L ^a   Chen, Zhong ^a   Waes, Carter Van ^a  

^a NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Cisplatinum; FANCD2; FANCF; Fanconi anemia; Mono ubiquitination; Squamous cell carcinoma

Indexed keywords

CISPLATIN; MESSENGER RNA;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER RISK; CARCINOMA CELL; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG SENSITIVITY; FANCA GENE; FANCC GENE; FANCD2 GENE; FANCE GENE; FANCF GENE; FANCG GENE; FANCL GENE; FANCONI ANEMIA; FANCONI ANEMIA GENE; FEMALE; GENE; GENE EXPRESSION; GENE INACTIVATION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; MALE; METHYLATION; ONCOGENE; PRIORITY JOURNAL; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; UBIQUITINATION; WESTERN BLOTTING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BRCA1 PROTEIN; BRCA2 PROTEIN; CARCINOMA, SQUAMOUS CELL; CELL SURVIVAL; CISPLATIN; FANCONI ANEMIA COMPLEMENTATION GROUP D2 PROTEIN; FANCONI ANEMIA COMPLEMENTATION GROUP PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 33845652128     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.12.028     Document Type: Article

References (17)

1. Alter B.P. Cancer in Fanconi anemia. Cancer 97 (2003) 425-440
2. D'Andrea A.D. The Fanconi road to cancer. Genes Dev. 17 (2003) 1933-1936
3. Bagby Jr. G.C. Genetic basis of Fanconi anemia. Curr. Opin. Hematol. 10 (2003) 68-76
4. Rosenberg P.S., Greene M.H., and Alter B.P. Cancer incidence in persons with Fanconi anemia. Blood 101 (2003) 822-826
5. Levitus M., Rooimans M.A., Steltenpool J., Cool N.F., Oostra A.B., Mathew C.G., et al. Heterogeneity in Fanconi anemia: evidence for 2 new genetic subtypes. Blood 103 (2004) 2498-2503
6. Meetei A.R., de Winter J.P., Medhurst A.L., Wallisch M., Waisfisz Q., van de Vrugt H.J., et al. A novel ubiquitin ligase is deficient in Fanconi anemia. Nat. Genet. 35 (2003) 165-170
7. Stavropoulos D.J., Bradshaw P.S., Li X., Pasic I., Truong K., Ikura M., et al. The Bloom syndrome helicase BLM interacts with TRF2 in ALT cells and promotes telomeric DNA synthesis. Hum. Mol. Genet. 11 (2004) 3135-3144
8. Meetei A.R., Yan Z., and Wang W. FANCL replaces BRCA1 as the likely ubiquitin ligase responsible for FANCD2 monoubiquitination. Cell Cycle 3 (2004) 179-181
9. Taniguchi T., and D'Andrea A.D. The Fanconi anemia protein, FANCE, promotes the nuclear accumulation of FANCC. Blood 100 (2002) 2457-2462
10. Pace P., Johson M., Tan W.M., Mosedale G., Sng C., Hoatlin M., et al. FANCE: the link between Fanconi anaemia complex assembly and activity. Eur. Med. Biol. Org. J. 21 (2002) 3414-3423
11. Taniguchi T., Garcia-Higuera I., Andreassen P.R., Gregory R.C., Grompe M., and D'Andrea A.D. S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51. Blood 100 (2002) 2414-2420
12. Marsit C.J., Liu M., Nelson H.H., Posner M., Suzuki M., and Kelsey K.T. Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene 23 (2004) 1000-1004
13. Taniguchi T., Tischkowitz M., Ameziane N., Hodgson S.V., Mathew C.G., Joenje H., et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat. Med. 9 (2003) 568-574
14. Kato T., Duffey D.C., Ondrey F.G., Dong G., Chen Z., Cook J.A., et al. Cisplatin and radiation sensitivity in human head and neck squamous carcinomas are independently modulated by glutathione and transcription factor NF-kappaB. Head Neck 22 (2000) 748-759
15. Cullen K.J., Newkirk K.A., Schumaker L.M., Aldosari N., Rone J.D., and Haddad B.R. Glutathione S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors. Cancer Res. 63 (2003) 8097-8102
16. Bradford C.R., Zhu S., Ogawa H., Ogawa T., Ubell M., Narayan A., et al. P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. Head Neck 25 (2003) 654-661
17. Oliver C.L., Bauer J.A., Wolter K.G., Ubell M.L., Narayan A., O'Connell K.M., et al. In vitro effects of the BH3 mimetic, (-)-gossypol, on head and neck squamous cell carcinoma cells. Clin. Cancer Res. 15 10 (2004) 7757-7763